United States Drug Patent 9,339,466: Scope, Claims, Expiration and ST-246 Patent Landscape

US Patent No. 9,339,466 protects Form I of ST-246, the active pharmaceutical ingredient in TPOXX (tecovirimat), together with selected pharmaceutical compositions and crystallization methods. Its central limitation is solid-state identity: the claimed material must exhibit the specified X-ray powder diffraction (XRPD) pattern. The patent does not broadly claim tecovirimat, all polymorphs, or every method of manufacturing the active ingredient.

The patent was assigned to SIGA Technologies, Inc. and issued May 17, 2016. Its nominal patent term runs into 2031 based on the disclosed priority and filing chronology, subject to any applicable patent-term adjustment, terminal disclaimer, or other USPTO term calculation.[1]

What drug does US Patent 9,339,466 protect?

US 9,339,466 protects Form I of ST-246, also known as tecovirimat or brincidofovir? The correct identity is tecovirimat. Tecovirimat is an antiviral small molecule used for treatment of human smallpox caused by variola virus and, under specified regulatory authorities, for monkeypox or mpox-related indications.

The claimed chemical entity is:

4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide

The commercial product TPOXX contains tecovirimat as the active ingredient. FDA approved oral TPOXX capsules in 2018 and later approved an intravenous formulation.[2][3]

US 9,339,466 is a solid-state patent. It is materially narrower than a composition-of-matter patent covering tecovirimat itself.

What is the core scope of US 9,339,466?

Claim 1 covers Form I of tecovirimat identified by an XRPD pattern with characteristic reflections at approximately:

2θ reflection angle
7.63°
10.04°
11.47°
14.73°
15.21°
15.47°
16.06°
16.67°
16.98°
18.93°
19.96°
20.52°
20.79°
22.80°
25.16°
26.53°
27.20°
27.60°
29.60°
30.23°
30.49°
30.68°
31.14°
33.65°
34.33°
35.29°
35.56°
36.30°
37.36°
38.42°
38.66°

The claim is product-by-structure and product-by-characterization. A competing product would face infringement risk if it contains tecovirimat in the claimed Form I, even if the manufacturer uses a different synthesis route.

The claim does not expressly require a particular particle size, morphology, purity threshold, excipient, dosage strength, capsule shell, or manufacturing scale.

How do claims 2 through 6 affect the purity scope?

Claims 2 through 6 create dependent composition-of-matter claims based on the amount of Form I relative to other polymorphic forms.

Claim	Minimum freedom from other forms
2	At least 70%
3	At least 80%
4	At least 90%
5	At least 95%
6	At least 99%

These claims create progressively narrower purity positions. Claim 1 does not state a numerical purity threshold. Claims 2 through 6 provide fallback positions if a court construes the independent claim narrowly or if prior art challenges the broader Form I claim.

The principal analytical issue is measurement. A dispute could arise over:

the analytical method used to quantify polymorph content;
whether amorphous material counts as another form;
whether solvates, hydrates, or residual solvent affect the calculation;
the meaning of “free of other forms”; and
whether the XRPD pattern must show every listed reflection or only a sufficient subset.

The patent specification and prosecution history would control those issues in litigation.[1]

What pharmaceutical compositions are protected?

Claim 7 covers a pharmaceutical composition comprising the claimed Form I and one or more conventional pharmaceutical ingredients. The listed ingredient categories include carriers, excipients, diluents, additives, fillers, lubricants, and binders.

Claim 8 narrows claim 7 to compositions formulated for oral administration.

The composition claims can reach an oral dosage form containing Form I even when the formulation uses excipients not individually named in the claim, provided the excipient falls within one of the listed categories. The claims do not appear limited to a particular dose, capsule size, dissolution profile, release profile, or brand formulation.

For TPOXX, the relevant commercial product is an oral capsule containing 200 mg of tecovirimat. FDA labeling identifies the product, route, strength, inactive ingredients, and approved administration instructions.[2]

What crystallization methods are claimed?

Claim 9 covers a process for producing Form I through controlled crystallization. The required steps are:

Dissolving ST-246 in at least one organic solvent and enough water to form a solution.
Cooling the solution to induce preferential crystallization of Form I.
Optionally drying the crystals.

The listed solvents are:

isopropyl alcohol;
ethyl acetate;
ethanol;
methanol;
acetone;
isopropyl acetate; and
tetrahydrofuran.

Claim 9 is narrower than a general process claim because it requires both a solvent-water system and cooling that preferentially crystallizes Form I.

How do claims 10 through 21 narrow the process?

Claims	Limitation
10	Addition of Form I seed crystals during cooling
11	Methanol or THF as an organic solvent
12	Cooling for at least 15 minutes
13	Cooling for at least 2 hours
14	Cooling for at least 5 hours
15	Ethyl acetate
16	Isopropyl alcohol
17	Ethyl acetate and about 40% water by total solvent volume
18	Ethyl acetate and about 5% water
19	Ethyl acetate and about 3% water
20	Ethyl acetate and about 2% water
21	Isopropyl alcohol and about 5% water

The process claims create multiple infringement routes. A manufacturer could avoid one dependent claim, such as the 40% water condition in claim 17, but still fall within claim 9 or another dependent claim if it uses the same solvent-water crystallization concept.

Claims 12 through 14 also create nested time limitations. A process cooling for five hours would ordinarily satisfy the “at least 15 minutes” and “at least 2 hours” limitations, assuming the other requirements are met.

When does US 9,339,466 expire?

The patent was filed in the United States in the 2011 period and claims priority to an earlier filing relating to ST-246 polymorphs. On a nominal 20-year term calculation, the patent extends into 2031.[1]

Milestone	Date
Priority period	2010
U.S. filing period	2011
U.S. publication	2011
Patent grant	May 17, 2016
Nominal expiration	2031, based on applicable priority-term calculation

The operative expiration date must be taken from USPTO term data because patent-term adjustment can add days, while terminal disclaimers can reduce effective term. The grant date does not determine expiration.

What is the FDA and Orange Book status of TPOXX?

FDA approved TPOXX oral capsules in July 2018 under NDA 212905.[2] The product is marketed by SIGA Technologies and is supplied through government procurement and commercial channels.

TPOXX is unusual because its principal commercial market is heavily influenced by federal strategic stockpiling, public-health procurement, and government contracts. Commercial prescription volume alone does not capture the product’s revenue exposure.

The Orange Book analysis should distinguish among:

patents listed for the approved drug product;
patents listed for approved methods of use;
patents covering the active ingredient or solid form;
patents covering a formulation or dosage form; and
regulatory exclusivity that is separate from patent protection.

A patent covering Form I may create commercial exposure for an ANDA applicant even if the applicant does not reproduce the branded capsule exactly. An ANDA applicant must address each listed patent through certification or a permissible statement under the Hatch-Waxman framework.[4]

Which companies are challenging TPOXX exclusivity?

The supplied record does not identify a specific Paragraph IV notice letter, ANDA filer, district-court action, or settlement involving US 9,339,466. A complete company-by-company challenge table cannot be established from the patent claims alone.

The main potential challenger categories are:

generic manufacturers filing ANDAs for oral tecovirimat capsules;
contract manufacturers seeking to supply government stockpiles;
active-ingredient manufacturers using a different polymorph or amorphous material;
manufacturers using a different crystallization route; and
sponsors developing alternative antiviral products.

A generic applicant using Form I would face a direct product claim risk. An applicant using a different solid form would reduce that risk but could encounter separate patents covering other forms, the active compound, formulations, methods of treatment, or manufacturing processes.

What Paragraph IV risks exist for a generic tecovirimat product?

A Paragraph IV strategy against US 9,339,466 could attack several claim elements:

XRPD identity

The applicant could argue that its product does not exhibit the claimed Form I pattern. This would require robust comparative XRPD testing under controlled conditions. Differences in instrument configuration, sample preparation, crystallinity, preferred orientation, and detection thresholds can affect the observed pattern.

Anticipation and obviousness

Prior art could be used to challenge whether Form I was previously disclosed or whether producing it would have been obvious. Relevant evidence would include:

earlier ST-246 solid-form disclosures;
crystallization experiments;
solvent and water systems;
seeding practices;
polymorph screening records; and
routine process-development knowledge.

Indefiniteness and claim construction

The terms “about,” “characteristic peaks,” “preferential crystallization,” and “free of other forms” could become central to a validity or infringement dispute. The strength of these arguments depends heavily on the specification, examples, prosecution amendments, and expert testing.

Process avoidance

A generic manufacturer can reduce process-claim exposure by using a different solvent system, antisolvent, temperature profile, seeding approach, or isolation procedure. Process avoidance does not eliminate product-claim risk if the resulting material is Form I.

How strong is the patent estate around TPOXX?

US 9,339,466 is strongest against manufacturers that use Form I or reproduce the claimed crystallization process. Its strength is narrower against manufacturers that:

produce a distinct polymorph;
use an amorphous form;
formulate a different solid state;
manufacture outside the claimed solvent and water conditions; or
sell a product protected only by an unlisted or expired compound patent.

The patent has four practical enforcement layers:

Layer	Commercial relevance
Form I product claim	Directly targets the solid form in API or finished product
Purity claims	Strengthen positions for high-purity Form I material
Oral composition claim	Targets oral dosage forms containing Form I
Crystallization claims	Targets selected manufacturing routes

The patent is therefore more significant for API sourcing and solid-form selection than for basic chemical synthesis.

What manufacturing and IP barriers affect generic entry?

A generic entrant must resolve both regulatory equivalence and solid-state control. Key technical barriers include:

maintaining the desired polymorph through milling and compression;
preventing conversion during storage;
controlling residual solvents and water activity;
matching dissolution and stability specifications;
demonstrating batch-to-batch XRPD consistency;
avoiding Form I contamination if pursuing a different form; and
preserving the selected form during tablet or capsule manufacture.

A manufacturer that intentionally avoids Form I may still need to prove that the alternative form remains stable under manufacturing and regulatory conditions. A product that converts to Form I during storage could create both quality and infringement issues.

How does US 9,339,466 compare with a composition-of-matter patent?

Issue	Composition-of-matter patent	US 9,339,466
Covered subject	Broad chemical compound	Specific polymorphic form
Design-around potential	Usually limited	Greater
Relevance to API sourcing	High	High if Form I is used
Relevance to finished product	Broad	Depends on solid form
Process dependence	Usually none	Product and process claims both present
Validity focus	Novel molecule and inventive step	Polymorph novelty, obviousness and characterization
Typical evidence	Chemical synthesis and biological data	XRPD, thermal analysis, crystallization and stability data

The patent should be analyzed with the broader tecovirimat compound, formulation, treatment-method, and manufacturing families. US 9,339,466 alone does not establish the full TPOXX exclusivity position.

Key Takeaways

US 9,339,466 protects Form I of tecovirimat, not tecovirimat in every physical form.
Claim 1 depends on the specified XRPD pattern.
Claims 2 through 6 cover Form I compositions with at least 70%, 80%, 90%, 95%, or 99% freedom from other forms.
Claims 7 and 8 cover pharmaceutical compositions, including oral formulations.
Claims 9 through 21 cover selected solvent-water cooling and seeding processes.
The nominal patent term extends into 2031.
A generic using Form I faces product-claim risk even if it uses a different synthesis route.
A generic using a different polymorph may avoid the principal product claim but must assess other tecovirimat patents and regulatory requirements.
TPOXX’s commercial exposure is shaped by federal procurement and stockpiling, not only ordinary prescription demand.
The supplied claim set does not establish a specific Paragraph IV challenger, litigation action, or settlement agreement.

FAQs

Does US 9,339,466 cover all tecovirimat polymorphs?

No. Its central product claim is limited to Form I identified by the specified XRPD reflections.

Can a generic avoid US 9,339,466 by using a different solvent?

Potentially. A different solvent may avoid some process claims, but it does not avoid the product claim if the resulting API is Form I.

Does the patent cover injectable TPOXX?

The supplied claims do not expressly require an injectable formulation. Claim 8 is limited to oral administration, while claim 7 is broader but still requires a composition containing the claimed Form I.

Is Form I purity of 99% required for infringement?

No. Claim 1 does not state a 99% threshold. The 99% purity limitation appears in dependent claim 6. The scope of claim 1 depends on how the XRPD and polymorph identity limitations are construed.

Are biosimilars relevant to TPOXX?

No. Tecovirimat is a chemically synthesized small molecule, so the principal competitive pathway is generic drug approval through an ANDA or another small-molecule regulatory route, not biosimilar approval.

References

SIGA Technologies, Inc. Polymorphs of ST-246, U.S. Patent No. 9,339,466 B2 (2016).
U.S. Food and Drug Administration. (2018). FDA approves the first drug with an indication for treatment of smallpox.
U.S. Food and Drug Administration. (2021). TPOXX (tecovirimat) prescribing information.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Siga Technologies	TPOXX	tecovirimat	CAPSULE;ORAL	208627-001	Jul 13, 2018		RX	Yes	Yes	9,339,466	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2549871	⤷ Start Trial	122022000033	Germany	⤷ Start Trial
European Patent Office	2549871	⤷ Start Trial	22C1023	France	⤷ Start Trial
African Regional IP Organization (ARIPO)	3221	⤷ Start Trial
Argentina	083435	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,339,466

Which drugs does patent 9,339,466 protect, and when does it expire?

Summary for Patent: 9,339,466